Repositioning Candidate Details
| Candidate ID: | R1030 |
| Source ID: | DB06495 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Onercept |
| Synonyms: | Onercept; R-HTBP-1 |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | -- |
| CAS Number: | 199685-57-9 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Tumor necrosis factor (TNF) is a proinflammatory cytokine that plays a pivotal part in the pathogenesis of Crohn’s disease (CD).1 A number of anti-TNF therapies have been developed for the treatment of CD. Onercept is a recombinant form of the soluble human p55 TNF-greek small letter alpha receptor (also known as TNF-binding protein 1) produced by recombinant DNA technology. Its putative mechanism of action involves neutralizing the effects of TNF by the formation of high-affinity complexes. |
| Targets: | Tumor necrosis factor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|